DRG Market Assessment reports

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both…

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…

Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…

Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected market penetration of the fourth anti-CGRP-…

Myelofibrosis (MF) is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and…

MARKET OVERVIEW Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disorder affecting hair follicles. Humira is the only FDA-approved therapy for the disease; its use is limited…

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of the most dynamic drug…

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant…

MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

DRG publishes a new primary market research report tracking awareness, trial, and use of Mylan’s Wixela Inhub, a therapeutic equivalent to Advair.  

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz) for the moderate to severe population,…